2017

On May 16th and 17th, 2017, ExL Events will host the Fourth Promotional Review Committee Compliance and Best Practices Conference…

In January, FDA’s Center for Drug Evaluation and Research (CDER) released its annual guidance agenda, announcing the new and…

With less than two days left to submit and attest to data for the June 30, 2017, publication, manufacturers and group purchasing…

Late last year, Bristol-Myers Squibb (BMS) settled with the government to resolve allegations that spanned several states that it…

We have seen many large False Claims and Anti Kickback settlements with pharmaceutical companies and the prescriptions…

In a city where crime rates are sky-high and illegal drugs are easily picked up on the street, on November 16, 2016, the City of…

On January 12, 2017, the U.S. Department of Justice (DOJ) announced publicly that Zimmer Biomet Holdings, Inc. (Zimmer…

Many in political (and non-political) circles have blamed a lack of pricing transparency for increasing healthcare costs. However,…

In a last-minute attempt to put a permanent mark on the life sciences (and specifically, the medical device) industry, the…

As many of our readers know all too well, pharmaceutical companies are not permitted to discuss off-label, legal, alternative uses…